Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venezuelan equine encephalitis vaccine C-84 is an inactivated, lyophilized (dried) viral vaccine developed by the U.S. Army Medical Research and Development Command (USAMRDC) for the prevention of Venezuelan equine encephalomyelitis (VEE). It is produced by the formalin inactivation of the TC-83 live-attenuated strain of the VEE virus. C-84 is primarily utilized as a booster for personnel at high occupational risk, such as laboratory workers, who have previously received the TC-83 vaccine but failed to achieve or maintain a protective neutralizing antibody titer (typically defined as < 1:20). Because it is an inactivated vaccine, it is generally used to supplement the primary immune response initiated by the live-attenuated vaccine in a heterologous prime-boost strategy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Venezuelan equine encephalitis vaccine C-84.